NASDAQ:CANB

Can B Competitors

$0.55
-0.01 (-1.79 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.50
Now: $0.55
$0.56
50-Day Range
$0.44
MA: $0.58
$0.88
52-Week Range
$0.25
Now: $0.55
$2.11
Volume267,032 shs
Average Volume124,557 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Can B (NASDAQ:CANB) Vs. ACHL, ADTX, CBDC, CDMOP, CBGL, and MTBCP

Should you be buying CANB stock or one of its competitors? Companies in the sector of "medical" are considered alternatives and competitors to Can B, including Achilles Therapeutics plc American Depositary Shares (ACHL), ADiTx Therapeutics (ADTX), Apotheca Biosciences (CBDC), Avid Bioservices (CDMOP), Cannabis Global (CBGL), and CareCloud (MTBCP).

Can B (NASDAQ:CANB) and Achilles Therapeutics plc American Depositary Shares (NASDAQ:ACHL) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, valuation, institutional ownership, risk and dividends.

Profitability

This table compares Can B and Achilles Therapeutics plc American Depositary Shares' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Can BN/AN/AN/A
Achilles Therapeutics plc American Depositary SharesN/AN/AN/A

Valuation & Earnings

This table compares Can B and Achilles Therapeutics plc American Depositary Shares' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Can BN/AN/AN/AN/AN/A
Achilles Therapeutics plc American Depositary SharesN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of current recommendations and price targets for Can B and Achilles Therapeutics plc American Depositary Shares, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Can B0000N/A
Achilles Therapeutics plc American Depositary Shares0000N/A

Can B (NASDAQ:CANB) and ADiTx Therapeutics (NASDAQ:ADTX) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, valuation, institutional ownership, risk and dividends.

Profitability

This table compares Can B and ADiTx Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Can BN/AN/AN/A
ADiTx TherapeuticsN/AN/AN/A

Valuation & Earnings

This table compares Can B and ADiTx Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Can BN/AN/AN/AN/AN/A
ADiTx TherapeuticsN/AN/AN/AN/AN/A

Analyst Ratings

This is a summary of current recommendations and price targets for Can B and ADiTx Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Can B0000N/A
ADiTx Therapeutics00103.00

Summary

ADiTx Therapeutics beats Can B on 1 of the 1 factors compared between the two stocks.

Can B (NASDAQ:CANB) and Apotheca Biosciences (NASDAQ:CBDC) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, earnings, risk and institutional ownership.

Profitability

This table compares Can B and Apotheca Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Can BN/AN/AN/A
Apotheca BiosciencesN/AN/AN/A

Earnings and Valuation

This table compares Can B and Apotheca Biosciences' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Can BN/AN/AN/AN/AN/A
Apotheca BiosciencesN/AN/AN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings and target prices for Can B and Apotheca Biosciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Can B0000N/A
Apotheca Biosciences0000N/A

Can B (NASDAQ:CANB) and Avid Bioservices (NASDAQ:CDMOP) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, earnings, risk and institutional ownership.

Profitability

This table compares Can B and Avid Bioservices' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Can BN/AN/AN/A
Avid BioservicesN/AN/AN/A

Earnings and Valuation

This table compares Can B and Avid Bioservices' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Can BN/AN/AN/AN/AN/A
Avid BioservicesN/AN/AN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings and target prices for Can B and Avid Bioservices, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Can B0000N/A
Avid Bioservices0000N/A

Can B (NASDAQ:CANB) and Cannabis Global (NASDAQ:CBGL) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, earnings, risk and institutional ownership.

Profitability

This table compares Can B and Cannabis Global's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Can BN/AN/AN/A
Cannabis GlobalN/AN/AN/A

Earnings and Valuation

This table compares Can B and Cannabis Global's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Can BN/AN/AN/AN/AN/A
Cannabis GlobalN/AN/AN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings and target prices for Can B and Cannabis Global, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Can B0000N/A
Cannabis Global0000N/A

CareCloud (NASDAQ:MTBCP) and Can B (NASDAQ:CANB) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.

Profitability

This table compares CareCloud and Can B's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CareCloudN/AN/AN/A
Can BN/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for CareCloud and Can B, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CareCloud0000N/A
Can B0000N/A

Valuation & Earnings

This table compares CareCloud and Can B's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CareCloudN/AN/AN/AN/AN/A
Can BN/AN/AN/AN/AN/A


Can B Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
ACHL
Achilles Therapeutics plc American Depositary Shares
0.0$13.78-5.3%$0.00N/A0.00Gap Down
ADiTx Therapeutics logo
ADTX
ADiTx Therapeutics
1.0$2.94-0.7%$0.00N/A0.00
Apotheca Biosciences logo
CBDC
Apotheca Biosciences
0.4$0.08-0.0%$0.00N/A0.00
Avid Bioservices logo
CDMOP
Avid Bioservices
0.3$25.06-0.0%$0.00N/A0.00
Cannabis Global logo
CBGL
Cannabis Global
0.0$0.11-2.3%$0.00N/A0.00
CareCloud logo
MTBCP
CareCloud
0.3$27.85-0.0%$0.00N/A0.00
FORA
Forian
0.3$11.42-7.2%$0.00N/A0.00Gap Up
Green Hygienics logo
GRYN
Green Hygienics
0.0$1.36-4.4%$0.00N/A0.00News Coverage
GLSI
Greenwich LifeSciences
1.7$53.60-5.8%$0.00N/A0.00High Trading Volume
News Coverage
Gap Down
Medigus logo
MDGS
Medigus
1.7$2.01-3.0%$0.00N/A0.00
RPHM
Reneo Pharmaceuticals
0.0$13.89-8.0%$0.00N/A0.00High Trading Volume
Gap Down
SCPS
Scopus BioPharma
1.4$7.57-6.2%$0.00N/A0.00Gap Down
The Greater Cannabis logo
GCAN
The Greater Cannabis
0.6$0.01-3.0%$0.00N/A0.00
VECT
VectivBio
0.0$24.23-29.8%$0.00N/A0.00High Trading Volume
News Coverage
Gap Up
This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.